FDA grants Brukinsa accelerated approval in relapsed or refractory marginal zone lymphoma – BeiGene
BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL)… read more.
